Chemoradiotherapy Versus Radiotherapy in Patients With Stage T1N0M0 Esophageal Cancer: A Retrospective Cohort Study.

The aim of this study is to compare the survival outcomes between radiotherapy and chemoradiotherapy in patients with stage T1N0M0 esophageal cancer. Stage T1N0M0 esophageal cancer patients treated with either radiotherapy or chemoradiotherapy were extracted from the Surveillance, Epidemiology, and End Results (SEER) database between 2000 and 2020. Cancer-specific survival (CSS) and overall survival (OS) were compared between the radiotherapy and chemoradiotherapy groups. A total of 41 patients (22.9%) underwent radiotherapy, while 138 patients (77.1%) received chemoradiotherapy. For stage T1a cases, chemoradiotherapy exhibited a similar 5-year CSS (35.9% vs. 26.1%; hazard ratio [HR] = 0.84, 95% confidence interval [CI]: 0.49-1.42; p = 0.511) and OS (24.1% vs. 10.0%; HR = 0.77, 95% CI: 0.50-1.20; p = 0.249) compared to radiotherapy. For stage T1b cases, chemoradiotherapy exhibited a similar 5-year CSS (33.4% vs. 18.2%; HR = 1.05, 95% CI: 0.41-2.70; p = 0.919) and OS (23.4% vs. 9.1%; HR = 0.68, 95% CI: 0.34-1.36; p = 0.272) compared to radiotherapy. Multivariable proportional hazards regression analysis confirmed that chemoradiotherapy was not an independent prognostic factor for CSS (HR = 0.89, 95% CI: 0.29-2.74; p = 0.833). However, chemoradiotherapy was an independent prognostic factor for OS (HR = 0.42, 95% CI: 0.19-0.94; p = 0.034). Radiotherapy is comparable to chemoradiotherapy in stage T1a cases. However, chemoradiotherapy is superior to radiotherapy in stage T1b patients.